ESMO 2025 | Phase Ia/b trial of IMA203, a PRAME-directed TCR therapy, in uveal melanoma
Sapna Patel, MD, Colorado Cancer Center, Aurora, CO, explores findings from a Phase Ia/b trial (NCT03686124/EudraCT 2019-002370-31) of IMA203, a PRAME-directed T-cell receptor therapy, in patients with advanced or metastatic uveal melanoma who had received prior treatment, including tebentafusp. The therapy demonstrated a high objective response rate and durable responses, with manageable cytokine release syndrome and limited neurotoxicity. These data suggest IMA203 may offer a promising new option for this difficult-to-treat patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
